Approach to and Treatment of Differentiated Thyroid Carcinoma

Medical Clinics of North America

Volumn 96, Issue 2, 2012, Pages 369-383

  Pacini, Furio ^a   Castagna, Maria Grazia ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

131I whole body scan; Radioiodine therapy; rhTSH; Thyroglobulin

Indexed keywords

AXITINIB; IODINE 131; LENVATINIB; LEVOTHYROXINE; MOTESANIB; PAZOPANIB; SORAFENIB; SUNITINIB; VANDETANIB;

BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; DRUG TARGETING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SUBTOTAL THYROIDECTOMY; THYROIDECTOMY;

CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE; TREATMENT OUTCOME;

EID: 84858788212     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.01.002     Document Type: Review

References (81)

1. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167.
2. Leenhardt L., Bernier M.O., Boin-Pineau M.H., et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004, 150:133-139.
3. Elisei R., Molinaro E., Agate L., et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010, 95:1516-1527.
4. Jemal A., Siegel R., Ward E. Cancer statistics 2006. CA Cancer J Clin 2006, 56:106-130.
5. Aschebrook-Kilfoy B., Ward M.H., Sabra M.M., et al. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011, 21:125-134.
6. Belfiore A., La Rosa G.L., La Porta G.A., et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992, 93:363-369.
7. Bosetti C., Bertuccio P., Levi F., et al. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008, 19:631-640.
8. SEER Cancer Statistics Review, 1975-2008 2011, National Cancer Institute, Bethesda (MD), Available at:, based on November 2010 SEER data submission, posted to the SEER web site. http://seer.cancer.gov/csr/1975_2008/, N. Howlader, A.M. Noone, M. Krapcho (Eds.).
9. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12:245-262.
10. Fugazzola L., Pilotti S., Pinchera A., et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 1995, 55:5617-5620.
11. Ito T., Seyama T., Iwamoto K.S., et al. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 1994, 344(8917):259.
12. Karga H., Lee J.K., Vickery A.L., et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 1991, 73:832-836.
13. Vasko V., Ferrand M., Di Cristofaro J., et al. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003, 88:2745-2752.
14. Marques A.R., Espadinha C., Catarino A.L., et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002, 87:3947-3952.
15. Nikiforova M.N., Biddinger P.W., Caudill C.M., et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002, 26:1016-1023.
16. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010, 20:697-706.
17. Pollina L., Pacini F., Fontanini G., et al. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 1996, 73:139-143.
18. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404.
19. Loh K.C. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 1997, 7:107-113.
20. Goldgar D.E., Easton D.F., Cannon-Albright L.A., et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600-1608.
21. Hemminki K., Eng C., Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 2005, 90:5747-5753.
22. Canzian F., Amati P., Harach H.R., et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998, 63:1743-1748.
23. Malchoff C.D., Sarfarazi M., Tendler B., et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000, 85:1758-1764.
24. Capezzone M., Marchisotta S., Cantara S., et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer 2008, 15:1075-1081.
25. Capezzone M., Cantara S., Marchisotta S., et al. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. J Clin Endocrinol Metab 2008, 93:3950-3957.
26. Nagataki S., Aashizawa K., Yamashita S. Cause of childhood thyroid cancer after the Chernobyl accident. Thyroid 1998, 8:115-117.
27. Mettler F.A., Williamson M.R., Royal H.D., et al. Thyroid nodules in the population living around Chernobyl. JAMA 1992, 5(268):616-619.
28. Anspaugh L.R., Catlin R.J., Goldman M. The global impact of the Chernobyl reactor accident. Science 1988, 16(242):1513-1519.
29. Pacini F., Vorontsova T., Molinaro E., et al. Thyroid consequences of the Chernobyl nuclear accident. Acta Paediatr Suppl 1999, 88:23-27.
30. Tronko M.D., Bogdanova T.I., Komissarenko I.V., et al. Thyroid carcinoma in children and adolescents in Ukraine after the Chernobyl nuclear accident: statistical data and clinicomorphologic characteristics. Cancer 1999, 86:149-156.
31. Jacob P., Bogdanova T.I., Buglova E., et al. Thyroid cancer among Ukrainians and Belarusians who were children or adolescents at the time of the Chernobyl accident. J Radiol Prot 2006, 26:51-67.
32. Sarne D., Schneider A.B. External radiation and thyroid neoplasia. Endocrinol Metab Clin North Am 1996, 25:181-196.
33. Ron E., Kleinerman R.A., Boice J.D., et al. A population-based case-control study of thyroid cancer. J Natl Cancer Inst 1987, 79:1-12.
34. Ron E., Lubin J.H., Shore R.E., et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995, 141:259-277.
35. Dean D.S., Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008, 22:901-911.
36. Rago T., Vitti P. Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008, 226:913-928.
37. Pacini F., Schlumberger M., Dralle H., European Thyroid Cancer Taskforce, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154:787-803.
38. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
39. Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009, 94:2092-2098.
40. Cantara S., Capezzone M., Marchisotta S., et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010, 95:1365-1369.
41. Elisei R., Bottici V., Luchetti F., et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004, 89:163-168.
42. Mazzaferri E.L., Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86:1447-1463.
43. American Joint Committee on Cancer: AJCC Cancer staging manual 2010, Springer, New York. 7th edition.
44. Tuttle R.M., Tala H., Shah J., et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the DRS American Thyroid Association staging system. Thyroid 2010, 20:1341-1349.
45. Castagna M.G., Maino F., Cipri C., et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011, 165(3):441-446.
46. Pacini F., Ladenson P.W., Schlumberger M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006, 91:926-932.
47. Pilli T., Brianzoni E., Capoccetti F., et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007, 92:3542-3546.
48. Chianelli M., Todino V., Graziano F.M., et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009, 160:431-436.
49. Elisei R., Schlumberger M., Driedger A., et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009, 94:4171-4179.
50. Tuttle R.M., Brokhin M., Omry G., et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008, 49:764-770.
51. Tuttle R.M., Lopez N., Leboeuf R., et al. 8. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 2010, 20:257-263.
52. Santini F., Pinchera A., Marsili A., et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 2005 Jan, 90(1):124-127.
53. Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006, 16:1229-1242.
54. Hovens G.C., Stokkel M.P., Kievit J., et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007, 92:2610-2615.
55. Pacini F., Capezzone M., Elisei R., et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002, 87:1499-1501.
56. Cailleux A.F., Baudin E., Travagli J.P., et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 2000, 85:175-178.
57. Smallridge R.C., Meek S.E., Morgan M.A., et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007, 92:82-87.
58. Iervasi A., Iervasi G., Ferdeghini M., et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol 2007, 67:434-441.
59. Schlumberger M., Hitzel A., Toubert M.E., et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007, 92:2487-2495.
60. Rosario P.W., Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays?. Clin Endocrinol 2008, 68:338-342.
61. Giovanella L., Maffioli M., Ceriani L., et al. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. Clin Chem Lab Med 2009, 47:1001-1004.
62. Spencer C., Fatemi S., Singer P., et al. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010, 20:587-595.
63. Castagna M.G., Tala Jury H.P., Cipri C., et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 2011, 34:219-223.
64. Malandrino P., Latina A., Marescalco S., et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 2011, 96:1703-1709.
65. Kloos R.T., Mazzaferri E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005, 90:5047-5057.
66. Castagna M.G., Brilli L., Pilli T., et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008, 93:76-81.
67. Crocetti U., Durante C., Attard M., et al. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid 2008, 18:1049-1053.
68. Brassard M., Borget I., Edet-Sanson A., THYRDIAG Working Group, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011, 96:1352-1359.
69. Kloos R.T. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 2010, 95:5241-5248.
70. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006, 91:498-505.
71. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
72. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999, 16:34-41.
73. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26:4708-4713.
74. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
75. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
76. Ahmed M., Barbachano Y., Riddell A., et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011, 165:315-322.
77. Carr L.L., Mankoff D.A., Goulart B.H., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16:5260-5268.
78. Bible K.C., Suman V.J., Molina J.R., Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11:962-972.
79. Sherman S.I., Jarzab B., Cabanillas M.E., et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011, 29:a5503. [abstract].
80. Hoftijzer H., Heemstra K.A., Morreau H., et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake in patients with differentiated thyroid cancer. Eur J Endocrinol 2009, 161:923-931.
81. Sherman S.I., Wirth L.J., Droz J.P., Motesanib Thyroid Cancer Study Group, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 3(359):31-42.